#USA #Nashville #KEYTRUDA #Thyme Care #Texas Oncology

Innovative Collaboration in Cancer Care

In a remarkable step towards reducing the financial burden of cancer treatment, Thyme Care and Texas Oncology have joined forces to implement weight-based dosing of the leading cancer drug, pembrolizumab, also known as Keytruda. This initiative operates under a shared value-based care agreement, showcasing the power of partnerships in improving patient care while simultaneously minimizing costs.

Purpose of the Collaboration

The collaboration is aimed specifically at their Medicare Advantage population, whose treatment experiences are greatly improved through this approach. For context, pembrolizumab is used to treat a wide range of cancers and is known for its effectiveness in enhancing life expectancy and overall quality of life for patients. Traditionally administered at a fixed dosage, recent studies have indicated that tailoring the dose based on individual patient weight not only maintains drug efficacy but also significantly cuts down treatment costs.

The Cost-Effectiveness of Weight-Based Dosing

One of the challenges in fee-for-service cancer treatment models is that they often do not provide incentives for adopting cost-effective practices. However, this initiative breaks that mold by integrating weight-based dosing into their protocols without transferring financial risk to healthcare providers. As a result, this model allows for practical implementation while aligning the goals of both Thyme Care and Texas Oncology towards improving outcomes for patients.

Dr. Debra Patt, Texas Oncology's Executive Vice President, highlights the innovative spirit of this partnership, stating, "Texas Oncology has long been a leader in bringing innovative, evidence-based care to our patients. Thyme Care made the economics work for our practice, enabling our clinical pharmacy team to scale this work across our broader patient population. This is what true value-based care looks like, and we're proud of what this partnership has accomplished."

Achievements and Findings

The analysis conducted between September 2025 and April 2026 reveals that more than half of the pembrolizumab doses administered were eligible for weight-based adjustments. Out of 613 doses analyzed, 34% converted to the new dosing structure, resulting in over $723,000 saved—equating to a notable 7.3% cut in projected costs.

The impact extended beyond the initial evaluation phase, showcasing nearly a 60% success rate in adherence to this methodology by June 2026. By equipping healthcare professionals with relevant data and insights, Thyme Care has been able to optimize the process and ensure that every eligible patient is identified for weight-based dosing.

Future Implications

As the landscape of oncology treatment evolves, particularly with the recent launch of a subcutaneous formulation of pembrolizumab, the Thyme Care and Texas Oncology partnership aims to replicate this successful model on similar high-value interventions that could lead to even more significant savings in cancer care.

This partnership is a powerful example of how healthcare organizations can work together to implement solutions that enhance patient care quality while managing costs effectively. It serves as a model for future initiatives in oncology care and beyond, demonstrating the potential of weight-based dosing and aligned financial incentives in delivering better outcomes for patients and communities alike.

About the Organizations

Thyme Care specializes in enhancing the cancer care journey by creating accountability among patients, providers, and insurance plans, all while driving down costs and improving outcomes through coordinated care and advanced technology solutions. To learn more about their impactful initiatives, visit thymecare.com.

Texas Oncology, founded in 1986, operates independently with over 550 physicians across more than 300 locations, delivering specialized services to over 250,000 cancer patients yearly. With a strong focus on research and clinical trials, Texas Oncology continues to lead advancements in cancer treatment collaborations. More can be explored at TexasOncology.com.